Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company creating a broad variety of next-generation protein therapeutics for oncology based on its proprietary, cell-free protein synthesis platform, XpressCF. Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. Sutro designs cytokine-based immuno-oncology therapies, antibody-drug conjugates, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. Sutro's platform allows it to accelerate discovery and development of first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.
Source
